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Antithrombotic agents are an integral component of the medical regimens and interventional strategies cur-
rently recommended to reduce thrombotic complications in patients with acute coronary syndromes (ACS). De-
spite great advances with these therapies, associated high risks for thrombosis and hemorrhage remain as the
result of complex interactions involving patient comorbidities, drug combinations, multifaceted dosing adjust-
ments, and the intricacies of the care environment. As such, the optimal combinations of antithrombotic thera-
pies, their timing, and appropriate targeted subgroups remain the focus of intense research. During the last sev-
eral years a number of new antithrombotic treatments have been introduced, and new data regarding
established therapies have come to light. Although treatment guidelines include the most current available data,
subsequent findings can be challenging to integrate. This challenge is compounded by the complexity associated
with different efficacy and safety measures and the variability in study populations, presenting syndromes, physi-
cian, and patient preferences. In this work we review recent data regarding clinically available antiplatelet and
anticoagulation agents used in the treatment of patients with ACS. We address issues including relative efficacy,
safety, and timing of therapies with respect to conservative and invasive treatment strategies. In specific cases
we will highlight remaining questions and controversies and ongoing trials, which will hopefully shed light in
these areas. In addition to reviewing existing agents, we take a look forward at the most promising new anti-
thrombotics currently in late-stage clinical development and their potential role in the context of ACS
management. (J Am Coll Cardiol 2009;54:969–84) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.083P
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Ahe large number of recent studies investigating various
ntithrombotic treatments necessitates a re-review of their
ole in managing patients with acute coronary syndromes
ACS). In this review, we focus on new data with clinically
vailable antiplatelet and anticoagulation agents (Table 1)
nd also take a look forward at promising new antithrom-
otics in late-stage clinical development.
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Antithrombotics in ACS September 8, 2009:969–84Association (AHA) (1–3) and Eu-
ropean Society of Cardiology (ESC)
(4–6) regarding the use of GPIs in
patients with ST-segment elevation
myocardial infarction (STEMI),
non–ST-segment elevation acute
coronary syndromes (NSTE-ACS),
and percutaneous coronary interven-
tion (PCI) are summarized in
Table 2.
NSTE-ACS. Use of an IV GPI or
clopidogrel prior to angiography is
a Class I recommendation in con-
junction with aspirin and an anti-
coagulant (1,5). In patients man-
aged conservatively, the use of
eptifibatide or tirofiban is a Class
IIa recommendation if high-risk
features are present (and Class IIb
otherwise) (1,5). New data avail-
able since the guidelines include
studies with GPIs: 1) on a back-
ground of 600 mg of clopidogrel;
2) comparing early versus late ini-
tiation; and 3) compared with
bivalirudin (see the section “Direct
thrombin inhibitors”).
Abciximab was evaluated in
2,002 patients with NSTE-ACS
pre-treated (2 h) with clopi-
dogrel 600 mg before PCI in
the placebo-controlled ISAR-
EACT 2 (Intracoronary Stenting and Antithrombotic Regi-
en–Rapid Early Action for Coronary Treatment) trial (7).
bciximab reduced the relative risk of the primary composite
f death, myocardial infarction (MI), or urgent target vessel
evascularization at 30 days by 25% (95% confidence interval
CI]: 3% to 42%, p  0.03); however, all of this early benefit
as observed in patients with increased levels of baseline
roponin (29% relative risk ratio, treatment-subgroup interac-
ion p 0.07). The use of abciximab did not increase the rate
f major bleeding (1.4% in both groups). The 1-year results of
SAR-REACT 2 (8) showed sustained benefit in the primary
nd point (23.3% vs. 28%, p  0.012) regardless of age, sex,
iabetes, or timing of clopidogrel (3 or 3 h) and was
resent even among patients with baseline negative troponin
in contrast to the 30-day results).
The ACUITY (Acute Catheterization and Urgent Inter-
ention Triage Strategy) trial randomized 13,819 patients
ith moderate- or high-risk ACS who were managed with
ngiography within 72 h to open-label heparin with GPI,
ivalirudin with GPI, or bivalirudin without GPI (9). In the
CUITY Timing Trial (subnested within the main trial),
he 9,207 patients in the 2 GPI arms underwent a second
Abbreviations
and Acronyms
ACC  American College of
Cardiology
ACS  acute coronary
syndromes
ADP  adenosine
diphosphate
AHA  American Heart
Association
CABG  coronary artery
bypass grafting
CrCl  creatine clearance
DTI  direct thrombin
inhibitor
ESC  European Society of
Cardiology
GPI  glycoprotein IIb/IIIa
inhibitor
LMWH  low molecular
weight heparin
MI  myocardial infarction
NSTE-ACS  non–ST-
segment elevation acute
coronary syndromes
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
UFH  unfractionated
heparinandomization to either early (at randomization) GPI or meferred selective GPI (at time of PCI) (10). At 30 days,
eferred GPI administration was associated with a nonsig-
ificant greater rate of composite ischemia (7.9% vs. 7.1%,
 0.13 superiority), which did not satisfy the criteria for
oninferiority compared with early GPI administration.
owever, major bleeding was reduced with deferred GPI
4.9% vs. 6.1%, p  0.001 for noninferiority, p  0.009
uperiority), whereas the rates of ischemic and bleeding
vents (net clinical outcome) were identical (11.7%). Nota-
le limitations of the ACUITY trial include its open-label
nd noninferiority design, use of various heparins and GPIs,
ower risk profile of patients compared with other contem-
orary studies, and short upstream infusion of GPI before
CI (4 h compared with approximately 24 h in a recent U.S.
egistry) (11,12).
The EVEREST (Randomized comparison of upstrEam
tandard dose tirofiban VERsus downstream high-doSe
irofiban or abciximab in high-risk ACS treated with PCI)
rial compared the effects of upstream standard-dose tirofi-
an (0.4 g/kg/min for 30 min followed by an infusion of
.10 g/kg/min for up to 12 h after PCI) to downstream
igh-dose bolus tirofiban (25 g/kg over 3 min, 10 min
efore PCI followed by 0.15 g/kg/min for 12 h) or
tandard-dose abciximab on tissue perfusion and biomarker
evels in 93 patients with high-risk NSTE-ACS treated
ith PCI (13). Overall upstream tirofiban was associated
ith improved tissue-level perfusion (lower frequency of
oor perfusion [Thrombolysis In Myocardial Infarction
TIMI] myocardial perfusion grade 0/1], greater myocardial
ontrast echo score index before and after PCI) and less
requent elevation in cardiac troponin-I after PCI. The
ARLY-ACS (Early Glycoprotein IIb/IIIa Inhibition in
on-ST-Segment Elevation Acute Coronary Syndrome)
rial (14) randomized 9,492 patients with NSTE-ACS
lanned for invasive management to a strategy of either
arly, routine administration of eptifibatide versus delayed,
rovisional use. There was no difference between strategies
n the primary outcome (death, myocardial infarction, re-
urrent ischemia requiring urgent revascularization, or
hrombotic bailout at 96 h), which occurred in 9.3% of
atients in the early-eptifibatide group compared with
0.0% in the delayed-eptifibatide group (odds ratio [OR]:
.92, 95% CI: 0.80 to 1.06, p 0.23), or key secondary end
oint (death or myocardial infarction at 30 days) 11.2%
ersus 12.3% (OR: 0.89, 95% CI: 0.79 to 1.01, p  0.08).
n addition, since there was more bleeding and transfusion
ith early routine use of eptifibatide, these data do not
upport the use of routine upstream GPI in NSTE-ACS.
TEMI. The current ACC/AHA (2) and ESC (6) STEMI
uidelines assign a Class IIa indication to the use of abciximab
Class IIb for eptifibatide and tirofiban) in patients treated with
rimary PCI and Class IIb recommendation for patients 75
ears of age treated with GPI and half-dose fibrinolytic as part
f a medical strategy (2,6). The authors of a recent European
eta-analysis (15) reported long-term results with abciximab
Mc
a
I
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September 8, 2009:969–84 Antithrombotics in ACSajor Recent Clinical Trials of Antiplatelet and Anticoagulants in NSTE-ACSTable 1 Major Recent Clinical Trials of Antiplatelet and Anticoagulants in NSTE-ACS
Trial Agent n Primary Results Note
NSTE-ACS
ISAR-REACT 2
Kastrati et al. (7)
JAMA 2006
GPI: abciximab vs. placebo 2,022 RRR of PE 25% at 30 days, p  0.03
with sustained benefit at 1 yr
p  0.012
Benefit in patients with elevated cTn at 30 days
and in all patients at 1 yr. Patients pre-
treated with 600 mg of clopidogrel.
EVEREST
Bolognese et al. (13)
J Am Coll Cardiol 2006
GPI: upfront tirofiban vs.
downstream GPI
93 TMPG 0/1 perfusion less frequent
with upstream tirofiban vs. high-
dose tirofiban or abciximab before
PCI (28.1% vs. 66.7% vs. 71%,
p  0.0009)
Upstream tirofiban also associated with less
frequent post-procedural cTnI elevation and
lower cTnI levels after PCI
EARLY-ACS
Giugliano et al. (14)
N Engl J Med 2009
GPI: routine early vs.
delayed provisional
eptifibatide
9,492 No difference in PE (9.3% vs. 10.0%,
p  0.23) between early routine
and delayed provisional groups
Trend toward fewer death/MI at 30 days
(11.2% vs. 12.3%, p  0.08), but more
bleeding and transfusion with early routine
eptifibatide.
ACUITY
Stone et al. (9)
N Engl J Med 2006
DTI: bivalirudin vs.
bivalirudin and GPI vs.
heparin and GPI
13,819 Bivalirudin alone noninferior for
composite ischemic EP (7.8% vs.
7.3%, p  0.32), reduced major
bleeding (3.0% vs. 5.7%,
p  0.001) and net clinical
outcome (10.1% vs. 11.7%,
p  0.02)
ACUITY Timing trial (10) showed more
composite ischemic events with deferred GPI
(7.9% vs. 7.1%, p  0.13 superiority), which
did not satisfy noninferiority
CURE
Yusuf et al. (22)
N Engl J Med 2001
Thienopyridine: clopidogrel
vs. placebo
12,562 Reduced composite end point with
clopidogrel (9.3% vs. 11.4%,
p  0.001)
Significantly more major bleeding with
clopidogrel compared to placebo (3.7% vs.
2.7%, RR: 1.38, p  0.001)
SYNERGY
Ferguson et al. (63)
JAMA 2004
LMWH: enoxaparin vs. UFH 10,027 No significant difference in PE with
enoxaparin (14% vs. 14.5%,
p  0.40)
Significant increase in TIMI major bleeding with
enoxaparin (9.1% vs. 7.6%, p  0.008)
OASIS-5
Yusuf et al. (85)
N Engl J Med 2006
LMWH: fondaparinux vs.
enoxaparin
20,078 Fondaparinux noninferior in PE (5.8%
vs. 5.7% p  0.007 noninferiority)
Reduced major bleeding with fondaparinux
(2.2% vs. 4.1%, p  0.001)
STEMI
FINESSE
Ellis et al. (16)
N Engl J Med 2008
GPI:  fibrinolytic
Abciximab  half dose of
reteplase vs. placebo
2,425 No difference in PE with combination
(GPI and fibrinolytic) or GPI vs.
placebo (9.8% vs. 10.5% vs.
10.7%, p  0.55)
Non ICH TIMI major bleeding through discharge
greater with combination (GPI and
fibrinolytic) (14.5% vs. 10.1% vs. 6.9%,
p  0.05)
On-TIME 2
Van’t Hof et al. (17)
Lancet 2008
GPI: high-dose tirofiban vs.
placebo before PCI
984 Significantly lower extent of mean
ST-segment deviation after PCI
with tirofiban (3.6 mm vs.
4.8 mm, p  0.003)
On background of clopidogrel 600 mg
HORIZONS-AMI
Stone et al. (78)
N Engl J Med 2008
DTI: bivalirudin vs. UFH
and GPI
3,602 Primary composite of ischemia and
bleeding reduced with bivalirudin
(9.2% vs. 12.1%, p  0.005)
Reduction in bleeding with bivalirudin (4.9% vs.
8.3%), but increase in stent thrombosis
(1.3% vs. 0.3%), both p  0.001
CLARITY–TIMI 28
Sabatine et al. (24)
N Engl J Med 2005
Thienopyridine: clopidogrel
vs. placebo in patients
planned for fibrinolytic
3,491 Significant reduction in PE with
clopidogrel vs. placebo (15% vs.
21.7%, p  0.001)
Similar rates of major bleeding and intracranial
hemorrhage between the 2 groups
COMMIT/CCS-2
Chen et al. (25)
Lancet 2005
Thienopyridine: clopidogrel
vs. placebo
45,852 Significant reduction in PE with
clopidogrel vs. placebo (9.2% vs.
10.1%, p  0.002)
No significant increase bleeding (fatal,
transfused, ICH) with clopidogrel
ExTRACT–TIMI 25
Antman et al. (68)
N Engl J Med 2006
LMWH: enoxaparin vs. UFH
in patients planned for
fibrinolytic
20,506 Significant reduction in PE with
enoxaparin vs. UFH (9.9% vs.
12.0%, p  0.001)
Enoxaparin group was treated throughout the
hospitalization. UFH group was treated for
48 h. Increased major bleeding was
observed with enoxaparin (2.1% vs. 1.4%,
p  0.001).
OASIS-6
Yusuf et al. (86)
N Engl J Med 2006
LMWH: fondaparinux vs.
UFH or placebo
12,092 PE reduced with fondaparinux in total
trial population (9.7% vs. 11.2%,
p  0.008)
Reduction in PE seen in Stratum I (no indication
for UFH, randomized to fondaparinux or
placebo), but not in Stratum II. Increased
rate of catheter thrombosis in PCI group
(n  0 vs. 22, p  0.001).
Across the spectrum of ACS (NSTE-ACS and STEMI)
TRITON–TIMI 38
Wiviott et al. (43)
N Engl J Med 2007
Thienopyridine: prasugrel
vs. clopidogrel
13,608 Significant reduction in PE with
prasugrel vs. clopidogrel (9.9% vs.
12.1%, p  0.001)
More major bleeding with prasugrel (2.4% vs.
1.8%, p  0.03)
Tn cardiac troponin; DTI direct thrombin inhibitor; GPI glycoprotein IIb/IIIa inhibitor; ICH intracranial hemorrhage; LMWH low molecular weight heparin; NSTE-ACS non–ST-segment elevation
cute coronary syndromes; PCI  percutaneous intervention; PE  primary end point; RRR  relative risk ratio; STEMI  ST-segment elevation myocardial infarction; TMPG  Thrombolysis In Myocardial
nfarction myocardial perfusion grade; UFH  unfractionated heparin.
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Antithrombotics in ACS September 8, 2009:969–84n 1,101 patients with STEMI treated with primary stenting
rescue PCI was an exclusion) in 3 placebo-controlled trials. At
-year follow-up, the use of abciximab significantly reduced
he rate of death or reinfarction (12.9% vs. 19%, p  0.008),
ith a trend toward lower rates of mortality (10.9% vs. 14.3%,
 0.052). There was no significant difference in major
leeding risks between the 2 arms.
The FINESSE (Facilitated Intervention with Enhanced
eperfusion Speed to Stop Events) trial (16) was the largest
tudy to date to investigate the strategy of facilitated PCI
ith GPI. A total of 2,452 patients were randomized in a
ouble-blind, double dummy manner to 1 of 3 arms:
bciximab with half dose reteplase (n  828), abciximab
lone (n  818), or placebo (n  806) before PCI. The last
roup received abciximab in the catheterization laboratory only
f PCI was performed. There was no difference in the primary
omposite end point of mortality, ventricular fibrillation after
8 h, cardiogenic shock, or congestive heart failure within 90
ays (9.8%, 10.5%, and 10.7% for the 3 treatment arms,
espectively; p  0.55) (Fig. 1A) despite greater rates of early
T-segment resolution with combination-facilitated PCI
43.9%, 33.1%, and 31.0%, respectively; p  0.01 and p 
.003, respectively). Moreover, the rates of nonintracranial
IMI major or minor bleeding through day 7/discharge
ere greater with combination facilitation (14.5%, 10.1%,
.9%; both p  0.05 compared with placebo).
In the ON-TIME 2 trial (17), 984 patients with STEMI
ho received aspirin, heparin, and 600 mg of clopidogrel
ere randomized to pre-treatment with high-dose tirofiban
r placebo prior to PCI. The primary end point of the
xtent of mean residual ST-segment deviation 1 h after PCI
as significantly lower in those receiving tirofiban versus
hose receiving placebo (3.6 mm vs. 4.8 mm, p  0.003). In
ontrast to FINESSE, patients treated with GPI had lower
ates of the composite of death, recurrent MI, urgent target
essel revascularization, or blinded bail-out use of tirofiban
urrent Guideline Recommendations for GPIIb/IIIa InhibitorsTable 2 Current Guideline Recommendations for GPIIb/IIIa Inh
Early Invasive/PCI
ACC/AHA (1–3) ESC (
STEMI (2,6) Class IIa (abciximab)
Class IIb (tirofiban, eptifibatide)
Class I (witho
Class IIa (wit
UA/NSTEMI (1,3–5) Class I (either GPI or clopidogrel
in addition to aspirin should
be initiated before
angiography)
Class IIa (reasonable to initiate
antiplatelet therapy with both
GPI and clopidogrel)
Class I (high
CC  American College of Cardiology; AHA  American Heart Association; ESC  European Soc
ercutaneous coronary intervention; UA  unstable angina; other abbreviations as in Table 1.26% vs. 32.9%, p  0.020) with no significant increase in tIMI major or TIMI minor bleeding (Fig. 1B). Patients in
n-TIME 2 presented sooner after symptoms compared
ith those in FINESSE (median 76 min vs. 126 min,
espectively), leading the authors to hypothesize that pa-
ients presenting late may not derive the same benefit from
pstream GP IIb/IIIa inhibition as those presenting early.
AFETY AND DOSING. The major risk of GPIs is primarily
leeding and to a lesser extent thrombocytopenia. Bleeding
isks increase as multiple antithrombotic agents are com-
ined, especially in certain vulnerable subgroups. In the
RUSADE (Can Rapid risk stratification of Unstable
ngina patients Suppress Adverse outcomes with Early
mplementation of the ACC/AHA guidelines) registry (18),
2% of patients received at least one initial dose of an
ntithrombotic drug outside of the recommended range,
nd 27% received an excess dose of GPI. Excess dosing was
ssociated with older age, female sex, renal insufficiency, low
ody weight, diabetes mellitus, and congestive heart failure.
atient who received an excess dose of GPI had 36% (95%
I: 10% to 68%) greater odds of a major bleed. The authors
stimated that 15% of major bleeding in the studied
opulation could be attributed to excess dosing of anti-
hrombotic therapies.
An analysis of 857 patients from the PROTECT (Ran-
omized Trial to Evaluate the Relative PROTECTion
gainst Post-PCI Microvascular Dysfunction and Post-PCI
schemia among Anti-Platelet and Anti-Thrombotic
gents)–TIMI 30 study with NSTE-ACS undergoing PCI
reated with eptifibatide and either heparin or low molecular
eight heparin (LMWH) also showed that older age was
ndependently correlated with bleeding (19). Among pa-
ients with estimated creatinine clearance (CrCl) 50
l/min, the maintenance infusion of eptifibatide was not
roperly adjusted downward (from 2 to 1 /kg/min) 45% of
he time, leading to high rates of bleeding (20%) and
s
Medical Management
ACC/AHA (1–3) ESC (4–6)
nting)
ting)
Class IIb (abciximab with half-dose lytic)
Patients age 75 yrs
Class III
Class I (if subsequent recurrent
symptoms/ischemia, heart failure, or
serious arrhythmia occur
angiography should be performed
with upstream administration of
either clopidogrel or GPI)
Class IIa (if recurrent ischemic
discomfort with clopidogrel, it is
reasonable to add a GP IIb/IIIa
antagonist before angiography)
Class IIb (may be reasonable to add GPI
to oral antiplatelet and anticoagulant
therapy)
Class II (high risk)
ardiology; GP  glycoprotein; NSTEMI  non–ST-segment elevation myocardial infarction; PCI ibitor
4–6)
ut ste
h sten
risk)ransfusions (27%).
SG
p
w
a
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September 8, 2009:969–84 Antithrombotics in ACSUMMARY. Extensive data support the use of intravenous
PIs in the setting of moderate- or high-risk NSTE-ACS,
Figure 1 Major Trial Findings in FINESSE and On-TIME 2
(A) Major findings in the FINESSE trial (16). The rates of complete (70%) ST-seg
fibrillation 48 h, cardiogenic shock, congestive heart failure) through 90 days, Th
not significantly different between patients randomized to abciximab facilitated per
combined rate of nonintracranial major or minor bleeding. (B) Major findings in the
clinical composite of death, recurrent myocardial infarction, urgent target vessel re
ban arm. There was no significant difference in TIMI major bleeding, TIMI minor ble
vessel revascularization, or major bleeding). NS  not significant.articularly if an early invasive strategy is planned. Patients pho present with STEMI who are undergoing primary PCI
lso appear to benefit; however, the benefit is less evident, in
esolution at 60 to 90 min, primary composite (all-cause mortality, ventricular
lysis In Myocardial Infarction (TIMI) major bleeding, or TIMI minor bleeding were
ous coronary intervention (PCI) versus primary PCI. Abciximab did increase the
ME 2 trial (17). The rate of complete ST-resolution after PCI was greater, and
larization, or blinded bail-out use of tirofiban at 30 days was lower in the tirofi-
, or net clinical outcome (death, recurrent myocardial infarction, urgent targetment r
rombo
cutane
On-TI
vascu
edingart because of the difficulty of diagnosing reinfarction early
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Antithrombotics in ACS September 8, 2009:969–84fter STEMI due to increased (and often still increasing)
ardiac markers. In the setting of low-risk ACS, GPIs may
ot be useful, and are potentially harmful, in troponin-
egative patients in whom a conservative management
trategy is planned, or if the bleeding risk is elevated.
lthough these agents have been available for more than
decade, and they have been studied extensively, open
uestions remain, including the timing of initiation, their
linical utility in combination with and compared with
ewer antithrombotics, and optimal dosing in certain
atient populations (i.e., the elderly, patients with renal
nsufficiency).
denosine diphosphate (ADP) antagonists. Clopidogrel
isulfate is a thienopyridine derivative, which is an antago-
ist for the P2Y12receptor. It is a pro-drug that first must be
bsorbed and metabolized by the liver cytochrome P450
nzymes into an active metabolite, which then binds irre-
ersibly to the receptor (20). The combination of clopi-
ogrel and aspirin has become the standard adjunctive
egimen in prevention of thrombotic events after intracoro-
ary stenting (21).
LOPIDOGREL AS AN ANTIPLATELET AGENT IN ACS. In the
URE (Clopidogrel in Unstable angina to prevent Recur-
ent Events) trial, dual antiplatelet therapy with clopidogrel
300-mg load, then 75 mg/day) for an average of 9 months
n addition to aspirin was found to be superior to aspirin
lone in preventing the composite end point of cardiovas-
ular death, MI, and stroke in 12,500 patients with
STE-ACS (22). This benefit also was observed in the
arge subset of patients who underwent PCI in the first
eeks of therapy, most of whom had received open-label
lopidogrel for four weeks after PCI (23).
More recently, both the CLARITY (CLopidogrel as Ad-
unctive ReperfusIon TherapY)–TIMI 28 angiographic trial
24) and the COMMIT/CCS-2 (ClOpidogrel and Metopolol
n Myocardial Infarction Trial/Chinese Cooperative Study)
ortality trial (25) provided solid evidence of the benefit of the
ombination of aspirin and clopidogrel in patients with
TEMI. Overall, in these trials, the safety profile of combina-
ion therapy appeared good, as there was no significant increase
n major bleeding rates compared with the addition of clopi-
ogrel. No loading dose was used in the COMMITT/CCS-2
rial, whereas in the CLARITY–TIMI 28 trial a 300-mg load
as used. Patients75 years of age (who are at greater risk of
ntracerebral bleeding) were excluded from CLARITY–TIMI
8. Therefore, it is important to stress that there are no safety
ata with a loading dose of clopidogrel in elderly patients
eceiving fibrinolytics or in patients with STEMI managed
ithout reperfusion therapy (at any age).
EED FOR PRE-TREATMENT. The authors of several studies
ave established the clinical benefit of pre-treatment with a
oading dose of 300 mg of clopidogrel on clinical outcomes
fter PCI. A post-hoc analysis of the CREDO (Clopidogrel
or the Reduction of Events During Observation) trial has
emonstrated that for clopidogrel to be fully effective, the coading dose of 300 mg of clopidogrel should be given at
east 15 h before intervention (26). Although this dose can
e readily implemented in patients undergoing elective PCI,
t is problematic when unplanned intervention is required in
n urgent setting.
The authors of recent studies have highlighted that a
reater loading dose of 600 mg clopidogrel achieves
uicker and greater platelet inhibition (27) and may result
n better clinical outcomes (28). In the recently com-
leted CURRENT–OASIS 7 (Clopidogrel Optimal
oading Dose Usage to Reduce Recurrent EveNTs–
ptimal Antiplatelet Strategy for InterventionS 7) study,
esearchers compared the safety and efficacy of a high-dose
egimen (600-mg load, followed by 150 mg/day for a week,
hen 75 mg/day for 3 weeks) versus a standard dose regimen
300-mg load, then 75 mg/day) of clopidogrel in approxi-
ately 14,000 patients with NSTE-ACS and PCI planned
ithin the next 24 h (29). Results are expected to be
eported this year.
Early pre-loading with clopidogrel may result in a greater
ate of perioperative bleeding if surgery is performed 5
ays after clopidogrel withdrawal (22). This concern has led
ome to advocate withholding clopidogrel in ACS patients
ntil the coronary anatomy is defined at least when early
oronary angiography is planned. However, the early phase
f ACS is the period of greatest risk, and if patients are not
eceiving GPIs, there is a concern that they may be left with
igh residual platelet activation when receiving aspirin
lone. The ESC guidelines (5), on these grounds as well as
he merit of simplicity, recommend against postponing the
dministration of clopidogrel until after angiography. Re-
ent observational data from the CRUSADE registry in
atients undergoing coronary artery bypass surgery (30), the
ajority of whom received clopidogrel within 5 days of
urgery, suggests that the modest increase in bleeding and
lood transfusion in those patients is not associated with a
etectable impact on the “hard” outcomes of death, rein-
arction and stroke.
ARIABILITY IN RESPONSE TO CLOPIDOGREL. The authors
f several studies have demonstrated that there is a wide
nterindividual variability in the response to clopidogrel, at
east in terms of inhibition of platelet response to ADP (31).
art of this variability may be genetically determined (32),
ependent upon clinical patient characteristics (33), and/or
esult from interactions with commonly used drugs such as
roton pump inhibitors (34), although the latter remains
ontroversial as detailed in a recent ACC/AHA/American
ollege of Gastroenterology joint statement (35). The
redictive value of an impaired response to clopidogrel is
ebated. Although a few studies (36,37) suggest that pa-
ients experiencing a stent thrombosis have suboptimal
nhibition of platelet aggregation on clopidogrel, the post
oc nature of many of these studies makes it difficult to
larify whether abnormal response to clopidogrel is the
ause or the consequence of stent thrombosis. A prospective
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September 8, 2009:969–84 Antithrombotics in ACStudy (38) performed in 804 patients (the majority with
CS) who underwent drug-eluting stent implantation
emonstrated for the first time that poor responders to
lopidogrel had a 3-fold increased risk of definite/
robable stent thrombosis and cardiac death.
Emerging studies suggest that greater, repeated doses of
lopidogrel may be effective to reduce complications in
atients with impaired response to clopidogrel (39). How-
ver, there is also wide variability in terms of assays used,
xperimental conditions, timing of assessment, and defini-
ions used for defining poor responders (40). In addition,
he optimal level of ex vivo platelet inhibition to have an
mpact on clinical outcomes in vivo is unclear. Given these
ncertainties, it is premature to embark on widespread
esting of the response of patients to clopidogrel or other
ntiplatelet agents, particularly given the modest amount of
ata regarding the proper clinical course of action if a poor
esponse is identified.
RASUGREL. New P2Y12 receptor antagonists are under
linical development, and one (prasugrel) has been approved
y the U.S. Food and Drug Administration. Prasugrel is a
hird-generation thienopyridine derivative that provides
uicker, greater, and more consistent inhibition of platelet
ctivation than clopidogrel (41,42). In the TRITON (Trial
o Assess Improvement in Therapeutic Outcomes by Op-
imizing Platelet Inhibition with Prasugrel)–TIMI 38 trial,
3,608 patients with moderate-to-high-risk NSTE-ACS or
TEMI who were scheduled to undergo PCI were ran-
omly assigned to receive prasugrel (60-mg load then 10
g/day) or clopidogrel (300-mg load then 75 mg/day) for a
ean duration of 14.5 months (43). The major efficacy end
oint (a composite of cardiovascular death, nonfatal MI, or
onfatal stroke) was significantly reduced from 12.1% in
atients receiving clopidogrel to 9.9% in patients receiving
rasugrel.
Importantly, the protective effect of prasugrel was ob-
erved across the full spectrum of ACS and was already
pparent 3 days after treatment start. Stent thrombosis also
as reduced (2.4% and 1.1%, respectively). However, the
eduction of ischemic events with prasugrel was achieved at
he expense of a 32% increase in TIMI major bleeding not
elated to coronary artery bypass grafting (CABG) (1.8%
nd 2.4%, respectively), including life-threatening bleeding.
xploratory subgroup analysis indicate that the safety/
fficacy balance of prasugrel might be particularly unfavor-
ble in patients with a history of stroke or transient ischemic
ttack, in elderly patients (age75 years), and in those with
body weight 60 kg.
ovel antiplatelet agents. Given the importance of the
latelet in the response to vascular injury and the clinical
enefit observed with a variety of approaches to interfering
ith platelet function, there have been multiple attempts to
urther improve upon both the safety and efficacy of antiplatelet
herapy. Current antiplatelet therapies typically are used in
ombination (for example, aspirin plus clopidogrel and/or GP aIb/IIIa inhibitors) for better efficacy with the recognition that
uch an approach creates the possibility of additional bleeding.
everal ADP P2Y12 inhibitors that achieve a high degree of
latelet inhibition (70%) are under clinical investigation.
hese agents aim to overcome some of the potential limita-
ions of clopidogrel, namely, delayed onset of action, modest
evel of platelet inhibition, wide variability in interpatient
harmacodynamic response (“hyporesponders” and “hyperre-
ponders”), and irreversible platelet inhibition (see also the
revious section “Prasugrel”).
Ticagrelor (formerly AZD6140) is an orally active, non-
hienopyridine, reversible, P2Y12 receptor antagonist (44).
ontrary to clopidogrel or prasugrel, it is active without the
equirement for metabolic activation and results in a high
evel of inhibition of ADP-induced platelet aggregation
45). It was recently compared with clopidogrel in
ISPERSE-2 (Dose confirmation Study assessing anti-
latelet Effects of AZD6140 vs. clopidogrel in non–ST-
egment Elevation myocardial infarction) (46), a phase 2
tudy in patients with ACS and demonstrated no increase in
ajor bleeding and favorable trends in rates of MI or the
omposite end point of cardiovascular death, MI, or stroke.
f note, the use of this agent is associated with an increase
n 2 adverse events: dyspnea and ventricular pauses. Al-
hough these side effects were of mild-to-moderate intensity
nd also were observed in patients treated with clopidogrel,
t will be important to assess their clinical impact in future
tudies. A very large clinical trial, PLATO (PLATelet
nhibition and patient Outcomes), compared ticagrelor with
lopidogrel in approximately 18,000 ACS patients, with a
rimary end point of cardiovascular death, MI, and stroke at
2 months. Top-line results announced in a press release
47) reported that ticagrelor reduced the primary composite
f vascular death, nonfatal myocardial infarction, or nonfatal
troke compared with clopidogrel, while achieving a similar
afety profile as in the DISPERSE-2 phase 2 study (46).
Cangrelor (formerly AR-C69931 MX) is a parenteral
irect P2Y12 receptor antagonist. It has a rapid onset of
ction and a plasma half-life of 5 to 9 min. After withdrawal
f therapy, platelet function returns to normal in approxi-
ately 20 min (48). The agent has linear kinetics, with no
nterference with renal or hepatic function. These charac-
eristics make it a potentially attractive agent for use in PCI
49,50). Two large randomized clinical trials tested cangre-
or in PCI (CHAMPION PCI [Cangrelor versus standard
herapy to achieve optimal management of platelet inhibi-
ion] and CHAMPION PLATFORM), with a composite
rimary end point of death, MI, and urgent target vessel
evascularization at 48 h. Recently, a press release reported
hat both CHAMPION trials were terminated early due to
ack of efficacy with cangrelor (51).
Therapeutic approaches that have incremental efficacy
hile minimizing additional bleeding liability would be
specially desirable. Such a concept might be possible
hrough agents that inhibit the platelet thrombin receptor
lso known as PAR. Recently, Becker et al. (52) published
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Antithrombotics in ACS September 8, 2009:969–84he TRA-PCI (Thrombin Receptor Antagonist Percutane-
us Coronary Intervention) study, in which they tested a
ovel PAR-1 inhibitor, also known as a thrombin receptor
ntagonist. These data suggested that high levels of
hrombin-induced platelet aggregation inhibition could be
btained in patients undergoing elective percutaneous in-
ervention while adding minimal bleeding risk to a regimen
f aspirin, clopidogrel, and a parenteral anticoagulant. This
ovel antiplatelet agent is now being studied in 2 large phase
clinical trials (TRA 2P [Thrombin Receptor Antagonist in
econdary Prevention of Atherothrombotic Ischemic Events]–
IMI 50 and TRACER [Thrombin Receptor Antagonist
or Clinical Event Reduction in acute coronary syndrome]).
art 2: Anticoagulants
eparin and LMWHs. The LMWHs are fragments of
nfractionated heparin (UFH) with a mean molecular
eight of approximately 5,000 Daltons (53). Similar to
FH, LMWHs exert their anticoagulant effect indirectly
ia antithrombin. However, with shorter chain lengths,
MWHs have less of an effect on thrombin (factor IIa) and
more preferential effect on factor Xa, along with less
lasma protein binding, better bioavailability, less platelet
ctivation, lower risk of immune-mediated thrombocytope-
ia (54), and significantly less activity on osteoclasts and risk
f bone loss than with UFH (55).
Although the bioavailability of LMWH is sustained
hen given subcutaneously, there are uncertainties regard-
ng the onset of effective anticoagulation, as well as an
nability to monitor or titrate drug levels. Although anti-Xa
ctivity can be measured in the laboratory, there is no clearly
stablished “therapeutic” range for the degree of anticoag-
lation that should be targeted, particularly in the setting of
CI. The LMWHs also are cleared renally; thus, in patients
ith renal insufficiency, a dose adjustment may be necessary
o avoid excessive bleeding complications. In a recent
ubstudy of ExTRACT (Enoxaparin and Thrombolysis
eperfusion for Acute Myocardial Infarction Treatment)–
IMI 25, multivariate analysis revealed that with every 30
l/min stratum decrease in CrCl, the risk of major and minor
leeding increased by 50% (56). Thus, adjusting the dose of
MWH by one-half may be necessary in patients with CrCl
30 ml/min, and its use in the presence of overt renal failure
equires further evaluation. Finally, in the presence of bleeding,
eversal with protamine only appears to neutralize approxi-
ately 60% of the antifactor Xa activity of LMWH. The
ecommended dose is 1 mg of protamine per 100 antifactor Xa
nits (1 mg enoxaparin  approximately 100 antifactor Xa
nits) if LMWH was given within 8 h (57).
Although numerous studies have been performed that
emonstrate the benefit (reduction in death and MI) of
hort-term UFH over placebo (58) in the setting of ACS,
umerous pharmacokinetic limitations of UFH have neces-
itated the study of more effective anticoagulants. A number
f trials have demonstrated the superiority of LMWH over tFH in the conservative management of patients with
STE-ACS (54,58). Although there have been several
tudies evaluating LMWHs in the setting of additional
djunctive pharmacologic therapies (59–61), further ques-
ions remain regarding the use of LMWHs in other
ettings, including in an early invasive strategy, in rapid
ransitions to the catheterization laboratory, for procedural
nticoagulation, and in conjunction with fibrinolytic therapy
or patients STEMI.
MWH IN THE INVASIVE MANAGEMENT OF NSTE-ACS.
revious trials (ESSENCE and TIMI 11B) (54) suggested
hat medically managed patients with NSTE-ACS treated
ith LMWH had no increase in bleeding complications if
hey were transferred to the catheterization laboratory, al-
hough in older studies this was relatively infrequent and these
ransfers did not proceed rapidly (Figs. 2A and 2B). The
uthors of other studies (60,61) have provided evidence on
atients receiving LMWH transferred to the catheterization
aboratory with a supplemental intravenous dose of LMWH at
he time of PCI. Additional larger studies have investigated
MWH in the context of an earlier invasive approach. The A
o Z (Aggrastatr to Zocor) study showed that in high-risk
CS patients managed with aspirin, tirofiban, and PCI the use
f enoxaparin (1 mg/kg subcutaneous twice a day) was nonin-
erior to UFH with no significant differences in TIMI major
nd minor bleeding (62).
The SYNERGY (Superior Yield of the New Strategy of
noxaparin, Revascularization, and Glycoprotein IIb/IIIa
nhibitors) study (63) included 10,027 high-risk patients
ith NSTE-ACS destined for an early invasive approach
ho were randomized to subcutaneous enoxaparin (1 mg/kg
wice a day) or weight-based UFH in addition to guideline-
ecommended aspirin, clopidogrel, and GPI. Patients ran-
omized to enoxaparin who arrived to the catheterization
aboratory 8 h after the last subcutaneous dose received an
dditional intravenous dose of 0.3 mg/kg before PCI. The
rimary end point (death or MI at 30 days) was not
ignificantly different between the 2 groups (14% with
noxaparin, 14.5% with UFH, p  0.40). However, there
as a significant increase in TIMI major bleeding with
noxaparin (9.1% vs. 7.6% with UFH, p  0.008) and,
lightly, although not significantly, greater rates of GUSTO
Global Use of Strategies to Open Occluded Coronary
rteries) major bleeding (2.7% vs. 2.2% with UFH, p 
.08) and transfusion (17% vs. 16% with UFH, p  0.16).
In patients already receiving UFH or LMWH who were
witched at randomization under controlled, protocol-
riven algorithms, there was no significant difference in
leeding between enoxaparin and UFH. Finally, patients
andomized to enoxaparin who crossed over (off protocol) to
FH had significantly greater bleeding rates. Thus, adding
FH to enoxaparin in an uncontrolled fashion (“stacking”
herapy), as opposed to a controlled, protocol-driven tran-
ition (Fig. 3), may result in increased bleeding complica-
ions. This issue was further highlighted in the recently
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September 8, 2009:969–84 Antithrombotics in ACSresented STACKENOX (STACK-on ENOXaparin)
tudy (64), which showed that adding UFH on top of
revious enoxaparin resulted in dramatic and prolonged
Figure 2 Trials of LMWHs
(A) Trials with LMWHs in ACS. Shown at the top are older clinical trials in STEMI
(left) and UA/NSTEMI (right). More recent data in both STEMI and UA/NSTEMI
and very recent data from CREATE (Clinical Trial of Reviparin and Metabolic Modu-
lation in Acute Myocardial Infarction Treatment Evaluation) and ExTRACT–TIMI 25
(in STEMI) and OASIS 5 (discussed in the Factor Xa inhibitors section, where enox-
aparin was the control arm) have provided additional guidance for the use of
LMWH in ACS. (B) Studies of LMWH in patients undergoing PCI. Shown at the
top (light background) are older observational studies of LMWH as procedural
anticoagulation (left) and in patients transitioned to the laboratory (right), most
frequently in previous ACS trials such as ESSENCE (Efficacy and Safety of Subcuta-
neous ENoxaparin in Non-Q-Wave Coronary Events), TIMI 11B, and FRISC II (FRag-
min and Fast Revascularisation during InStability in Coronary artery disease). More
recent randomized data for procedural anticoagulation and from large contempo-
rary ACS trials where LMWH patients were brought to the catheterization labora-
tory, as well as very recent data from STEEPLE (for procedural anticoagulation) and
ExTRACT–TIMI 25 and OASIS 5 (where enoxaparin patients were transitioned to
the catheterization laboratory) have provided useful new information on the use
of LMWH in the catheterization laboratory. ACS  acute coronary syndrome;
LMWH  low molecular weight heparins; NSTEMI  non–ST-segment elevation
myocardial infarction; UA  unstable angina; other abbreviations as in Figure 1.ncreases in coagulation parameters. tMWH DURING PCI. The authors of several early studies
65,66) examined the use of intravenous LMWH as an
lternative to UFH as procedural anticoagulation for PCI
nd found that LMWH in a nonemergent procedural PCI
etting was as efficacious as UFH, with similar bleeding risk
Fig. 2B). Researchers from the STEEPLE (Safety and
fficacy of Enoxaparin in Percutaneous Coronary Interven-
ion Patients, an International Randomized Evaluation)
rial (67) examined the use of procedural intravenous enox-
parin in 3,528 patients undergoing nonurgent PCI. Pa-
ients were randomized to IV enoxaparin (0.5 or 0.75
g/kg) or intravenous (IV) UFH (50 to 70 U/kg or 70 to
00 U/kg) with or without a GPI. The primary end point,
on–CABG-related major plus minor bleeding at 48 h,
ccurred in 6%, 6.6%, and 8.7% of the 0.5 mg/kg IV
noxaparin group, 0.75 mg/kg IV enoxaparin group, and IV
FH group, respectively (p  0.014 for 0.5 mg/kg enox-
parin vs. UFH and p  0.052 for 0.75 mg/kg enoxaparin
s. UFH). There was no statistically significant difference in
eath, nonfatal MI, or urgent target vessel revascularization
t 30 days. By multivariate analysis, assignment to the
noxaparin group was an independent predictor of reduced
ajor plus minor bleeding.
MWH IN STEMI. The ExTRACT–TIMI 25 trial (68)
nvolved 20,506 patients with STEMI who were random-
zed to enoxaparin (30 mg IV, then 1 mg/kg twice a day
ntil hospital discharge; in patients 75 years of age, no
olus was given, and the subcutaneous dose was reduced to
.75 mg/kg twice a day) or UFH (weight-based, activated
artial thromboplastin time-adjusted) for at least 48 h. The
rimary end point of death/nonfatal MI at 30 days was
ignificantly lower in the enoxaparin group (9.9% vs. 12%
ith UFH, p  0.001), primarily driven by a significant
eduction in reinfarction. In the overall study there was a
ignificant increase in TIMI major bleeding (2.1% vs. 1.4%
ith UFH; p  0.001) with no differences in ICH. It is
mportant to note that treatment durations were, by design,
ot equivalent in the 2 groups (mean 7 days with enoxapa-
in, 48 h with UFH); therefore, the question of the impact
f variable duration of therapy remains unanswered.
The treatment benefits of enoxaparin appeared to emerge
y 48 h (while both groups were receiving active therapy),
ith a nonsignificant trend in death or nonfatal MI (4.7%
s. 5.2% with UFH; p 0.08) and a significant difference in
eath, nonfatal MI, or urgent revascularization (5.3% vs.
.1% with UFH; p 0.02) through 48 h. These reductions,
owever, were relatively small in comparison with the
verall reductions at 30 days, suggesting that continued
n-hospital therapy with enoxaparin provided substantial
dditional benefit. In a recent analysis of 4,676 patients
rom ExTRACT undergoing PCI within 30 days of ran-
omization, there was a significant reduction in death/MI,
rgent revascularization, and stroke in the enoxaparin
roup, whereas TIMI major and minor bleeding was similar
o the UFH group (69).
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Antithrombotics in ACS September 8, 2009:969–84EAL-WORLD CONCLUSIONS. In numerous clinical trials, in-
luding a recent meta-analysis of 22,000 patients (70), the
se of LMWH appears to be a viable treatment option across
wide clinical spectrum of patients presenting with ACS. The
se of LMWH appears safe and effective in patients undergo-
ng a controlled transition to the catheterization laboratory
SYNERGY), during PCI (STEEPLE), and in fibrinolytic-
reated STEMI (ExTRACT–TIMI 25), including those go-
ng on to elective or urgent PCI (ExTRACT PCI). As
MWH becomes integrated into more broad-based ACS
reatment strategies, it must be investigated in the future
or potential use in other settings such as primary PCI for
cute MI.
irect thrombin inhibitors (DTIs). Increasingly, throm-
in is viewed as functioning at the complex interface of
issue injury, hemostasis, and platelet response (71). The
TIs act by binding to thrombin and blocking its interac-
ion with substrates in this multifaceted, redundant, and
nteractive biological system. Not only can DTIs directly
lock the formation of fibrin from fibrinogen by the action
f thrombin, but they also can block the feedback activation
f coagulation factors by thrombin (72) and inhibit the
hrombin-induced component of platelet aggregation (73).
he dual activity on fluid-phase thrombin and fibrin-bound
hrombin gives DTIs a conceptual advantage over indirect
pstream inhibitors in that the accretion of thrombi may be
ore effectively inhibited. The conceptual disadvantage is
he risk that upstream prothrombotic elements may accu-
ulate during DTI activity, leading to the risk of rebound.
urrently, 3 DTIs are available for use in the setting of
Figure 3 Antithrombotic Protocol Used in SYNERGY
The SYNERGY trial (63) used a pre-specified protocol to transition patients in a co
fashion to/from UFH and LMWH. UFH  unfractionated heparin; other abbreviationrterial thrombosis: lepirudin, argatroban, and bivalirudin; iowever, this state-of-the-art review will focus on the latter
iven the more promising recent data with bivalirudin in
CS.
Bivalirudin is a synthetic bivalent inhibitor that consists
f 20 amino acids that are slowly cleaved by thrombin at the
ctive site, permitting gradual recovery of some of throm-
in’s functionality (74). When initially administered, it
herefore begins as a noncompetitive thrombin inhibitor but
radually becomes a competitive inhibitor because of this
eturn of thrombin functionality. It is cleared predominately
y proteolytic cleavage but also has a significant component
f renal clearance with a half-life of 25 min. Bivalirudin has
een widely studied in conjunction with percutaneous cor-
nary revascularization and may soon be available for
reatment of NSTE-ACS when the aggressive interven-
ional approach is used.
Interestingly, although no DTIs are currently approved
or use in ACS, the largest mass of clinical trial data
oncerning DTIs was acquired in the setting of ACS. The
uthors of a key systematic overview (75) used patient-level
ata pooled across multiple trials comparing DTIs with
FH in 35,000 patients with either STEMI or NSTE-
CS. The primary result was that, overall, the DTIs
educed the composite of death and nonfatal MI by 15% on
he relative scale and 0.8% on the absolute scale; however,
here was no significant reduction in total mortality com-
ared with UFH, and there was a modest increase in
leeding. However, significant heterogeneity was observed
n 2 aspects: the bivalent inhibitors (hirudin and bivalirudin)
ere more effective versus UFH than were the univalent
d
n Figure 2.ntrolle
s as inhibitors (which actually appeared to be detrimental rela-
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September 8, 2009:969–84 Antithrombotics in ACSive to UFH); and bivalirudin led to a markedly lower rate
f bleeding than UFH, while the other DTIs had more
leeding.
Considerable interest has developed in the use of biva-
irudin for ACS and PCI. Multiple trials have firmly
stablished that bivalirudin is a reasonable therapy in both
linical conditions, although the clinical and expert com-
unities remain divided in their interpretation of how
xtensively the results of these trials should be applied in
ractice. The authors of the REPLACE II (Randomized
valuation in PCI Linking Angiomax to Reduced Clinical
vents) study (76) compared a regimen of bivalirudin and
PI for “bailout” with a regimen of UFH and GPI with a
rimary end point of noninferiority for a triple composite
nd point of death, nonfatal MI, and major bleeding (77).
he trial has been interpreted by its advocates to demon-
trate that bivalirudin is noninferior to a combination of
FH and GPI in PCI; however, others believe that the
tudy design prevents definitive interpretation: the nonin-
eriority margins were borderline, the patient population
as low-risk, the end point definitions emphasized small
ifferences in bleeding (in favor of bivalirudin) and de-
mphasized differences in markers of cardiac necrosis (again
n favor of bivalirudin), and the use of the comparator
reatments was suboptimal.
Similarly, in the ACUITY trial (9) bivalirudin with GPI
as noninferior in terms of the 30-day composite ischemia
nd point (7.7% vs. 7.3% p  0.39), major bleeding (5.3%
s. 5.6% p 0.38), and the net clinical end point (11.8% vs.
1.7% p  0.93) when compared with heparin with GPI.
ivalirudin alone was associated with a noninferior rate of
he ischemia end point and significantly lower rates of major
leeding (3.0% vs. 5.7%, p  0.001) as well as the net
linical end point (10.1% vs. 11.7%, p  0.02). At 1 year,
he rates of composite ischemia and mortality remained
imilar in patients treated with bivalirudin alone when
ompared with heparin (unfractionated or enoxaparin) plus
PI regardless of patient risk. The mortality benefit was
ndependent of the timing of clopidogrel administration. In
ddition, switching to bivalirudin from unfractionated hep-
rin or enoxaparin also appeared to be associated with
imilar benefits of reduced bleeding and protection for the
omposite or ischemia and death at one year.
In the HORIZONS-AMI (Harmonizing Outcomes
ith Revascularization and Stents in Acute Myocardial
nfarction) trial (78), 3,602 patients with STEMI undergo-
ng primary PCI were randomized to either open-label
ivalirudin monotherapy or heparin and GPI. Bivalirudin
onotherapy reduced the primary composite of ischemic
vents or bleeding by 24% (9.2% vs. 12.1%, p  0.005),
riven entirely by a 40% reduction in bleeding (4.9% vs.
.3%, p  0.001) (Fig. 4). There was a 1% absolute excess
n acute stent thrombosis with bivalirudin monotherapy
1.3% vs. 0.3%, p  0.001), which possibly was related to
nsufficient antiplatelet effect in the first 24 h despite a load
f 600 mg of clopidogrel. Nonetheless, death from cardiac iauses were reduced with bivalirudin (1.8% vs. 2.9%, p 
.03).
Again, concerns about the specifics of the comparator
egimens, patient populations, and definitions have led to
ealthy debate about the pragmatic interpretation of these
rials. However, the pattern of effective reduction in isch-
mic events compared with putative placebo and a very
avorable profile for bleeding is consistent throughout these
rials. In summary, bivalirudin is established as a viable
onotherapy in the setting of “nonhigh-risk” PCI (79) and
ay soon be available for ACS in situations in which an
ggressive, angiographically driven strategy is planned. The
rofile supports use of bivalirudin particularly in patients at
igh risk of bleeding, except in the case of MI treated with
brinolytic agents, in which an appropriate dose has not yet
een developed (80).
The future may bring expanded use of DTIs. The
evelopment of an effective, safe, orally available DTI has
een a major challenge for the pharmaceutical industry.
imelagatran was a highly touted, orally administered DTI
hat, despite many favorable characteristics, was not ap-
roved by the U.S. Food and Drug Administration and was
ithdrawn from the market in Europe because of evidence
f hepatotoxicity combined with questions about the dem-
nstrated benefit compared with warfarin (81). Currently, at
east 7 DTIs are being examined in clinical trials that are
valuating their use in deep venous thrombosis, ischemic
eart disease, and atrial fibrillation. The oral DTI dabigat-
an (82) is farthest along the path of development, with
ajor trials underway in all 3 arenas.
actor Xa inhibitors. Fondaparinux is a synthetic analog
f the pentasaccharide sequence in heparin that has a
eversible binding to antithrombin but induces irreversible
onformational changes, leaving the antithrombin activated
lso after dislocation of fondaparinux (83,84). As with
MWH, fondaparinux has complete subcutaneous avail-
bility and a longer half-life, allowing its administration as
once-daily dose for all indications. Fondaparinux has been
ested in daily fixed doses ranging from 2.5 mg up to 7.5 mg.
urprisingly, the lowest dose of 2.5 mg was tested and
ocumented to be efficacious in NSTE-ACS and STEMI,
s outlined in the next section. Beside the expected side
ffects of bleeding, the treatment is associated with very few
ide effects.
ONDAPARINUX IN NSTE-ACS. The efficacy and safety of
ubcutaneous fondaparinux 2.5 mg daily was compared with
outine treatment with enoxaparin 1 mg/kg body weight for
days or until hospital discarge in the OASIS-5 trial (85).
n this study, 20,078 patients with NSTE-ACS were
andomized to either of these 2 treatments within 24 h after
tart of symptoms. The primary objective of showing
oninferiority concerning the efficacy outcome of death,
I, or refractory ischemia at 9 days was fulfilled (p 0.007)
ith 5.8% events in the fondaparinux compared with 5.7%
n the enoxaparin group. However, major bleeds were
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Antithrombotics in ACS September 8, 2009:969–84alved (2.2% with fondaparinux compared with 4.1% with
noxaparin, p  0.001). Accordingly, the net clinical out-
ome of the composite of death, MI, refractory ischemia, or
ajor bleeding was lower with fondaparinux (7.3% com-
ared with 9.0% with enoxaparin, p  0.001). Importantly,
ong-term mortality after 6 months was lower with fondapa-
inux 5.8% compared with 6.5% with enoxaparin (p 
.05). Also, at this time point the net clinical benefit of the
omposite of death, MI, or stroke was reduced with
ondaparinux (11.3% compared with 12.5% with enoxapa-
in, p  0.007). Interestingly, long-term mortality was
ssociated with the occurrence of earlier major bleeding,
hereby emphasizing the importance of the reduced bleed-
ng rate with fondaparinux as compared with enoxaparin.
During the trial, there were observations of catheter-
elated thrombi occurring more frequently with the use of
ondaparinux (0.9% compared with 0.4% with enoxaparin,
 0.001). In addition, there tended to be more clinical
CI-related coronary complications with fondaparinux
9.5% compared with 8.6% with enoxparin, p  0.21).
here was, however, a lower rate of puncture-related bleed-
ngs with fondaparinux (3.3% compared with 8.1% with
noxaparin, p  0.001). Therefore, the composite of
rocedure-related complications including death, MI, or
Figure 4 Main Results From HORIZONS-AMI
In HORIZONS-AMI (78), bivalirudin (Bival) was reduced the primary end point of ne
(CABG) bleeding and major adverse cardiovascular events) and major non-coronary
IIIa inhibitor (GPI). There was no difference in the composite of major adverse card
tion for ischemia [TVR], or stroke).leeding was significantly less frequent with fondaparinux than with enoxaparin (16.6% compared with 20.6%, p 
.001). The overall conclusions from the trial were that
ondaparinux, as compared with the currently recommended
outine treatment with enoxaparin, reduces the risk of
leeding and lowers long-term morbidity and mortality (5).
etrospectively, the investigators learned during the trial
hat the greater risk of catheter-related thrombi might be
voided by using UFH during the procedure without losing
he advantage with regard to reduction in bleeding.
ONDAPARINUX IN STEMI. Fondaparinux also has been
valuated as an alternative to standard adjuvant anticoagu-
ant treatment in STEMI (86). In the OASIS-6 trial,
2,092 patients were randomized to subcutaneous fondapa-
inux 2.5 mg daily during 8 days or until hospital discharge
nd compared with subjects who received standard treat-
ent with UFH or no anticoagulant treatment. In Stratum
(no indication for UFH), 5,658 patients were randomly
llocated to fondaparinux or placebo. In Stratum II, 6,434
atients were randomized to fondaparinux in comparison
ith an infusion of UFH for 48 h, followed by placebo for
days or until hospital discharge. Within both strata there
ere subgroups with and without reperfusion treatments.
mong those in whom reperfusion therapy was adminis-
se clinical events (composite of major non-coronary artery bypass grafting
bypassing grafting (CABG) bleeding compared to heparin and glycoprotein IIb/
ular events (composite of death, reinfarction [ReMI], target vessel revasculariza-t adver
artery
iovascered, different modes were used. Thrombolysis was admin-
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September 8, 2009:969–84 Antithrombotics in ACSstered in 5,436 patients and was dominated by nonfibrin-
pecific lytics (84%). Primary PCI was used in 3,789
atients, of whom 99% were in Stratum II.
In the total trial population the composite primary end
oint of death or reinfarction at 30 days was reduced from
1.2% to 9.7% with the use of fondaparinux (p  0.008).
he reduction was only observed in Stratum I (without
ndication for UFH), with a reduction from 14.0% to 11.2%
p  0.001) with fondaparinux. In Stratum II (with indi-
ation for UFH) there was no difference, with 8.3% in the
FH/placebo group versus 8.7% in the fondaparinux group.
n the subgroup treated with primary PCI, there was a trend
f harm with fondaparinux, with a 30-day rate of death or
I of 6.1% with fondaparinux compared with 5.1% in the
FH group (p  0.19). In the fondaparinux group there
as also a greater rate of catheter-related thrombosis (n 
vs. 22; p  0.001) and more coronary complications (n 
25 vs. 270; p  0.04). In the other 2,666 patients in
tratum II (with indication for UFH but without primary
CI), there was a trend to benefit with fondaparinux versus
FH/placebo, with a reduction from 13.8% to 11.5% in the
omposite of death or MI at 30 days (p  0.08). There was
lso a trend toward fewer major bleeds with fondaparinux
hen combining both strata.
The conclusions of the trial were that in acute STEMI
ithout indication for UFH, fondaparinux is more effective
nd as safe as no anticoagulant treatment, regardless of whether
ny reperfusion treatment with streptokinase is used (30). In
ther STEMI patients treated with thrombolytics with an
ndication for UFH (i.e., fibrin-specific agents such as alte-
lase), fondaparinux for 8 days (or until discharge) seems at
east as effective and as safe as a UFH infusion for 48 h. In
TEMI patients treated with primary PCI, fondaparinux
ppears to be associated with a risk of harm, on the basis of an
ncreased rate of coronary complications.
RAL FACTOR Xa INHIBITORS. Currently, a number of
ntravenous and oral direct factor Xa inhibitors have entered
linical development. In contrast to antithrombin-mediated
nhibition, these compounds inhibit factor Xa both when
ree in the circulation and when bound within the pro-
hrombinase complex. Some information on the initial
linical results and the development programs are currently
vailable for at least 1 IV (otamixaban) (87) and several oral
nhibitors of factor Xa: edoxaban (DU-176b) (88), apixaban
89), rivaroxaban (90), waroxaban (LY 5157117) (91), and
M 150 (92). The majority of the available clinical data are
elated to the efficacy and safety of the oral inhibitors of
actor Xa in phase 2 to 3 studies on the prevention of
enothromboembolism after major orthopedic surgery. In
egard to otamixaban, results of a phase 2 study in the
ontext of PCI have recently been published (87). Rivar-
xaban, apixaban, and edoxaban are currently under evalu-
tion in phase 3 studies of stroke prevention in atrial
brillation and/or secondary prevention after ACS. To date,
he hepatic safety profile reported with oral factor Xa unhibitors compares favorably to that described with ximel-
gatran (see the section “Direct thrombin inhibitors”).
ovel anticoagulants. Both oral and parenteral anticoagu-
ants under development seek to improve upon currently
vailable therapeutic approaches. New anticoagulants can be
ivided into 3 groups based on their primary target in the
oagulation cascade: 1) inhibitors of initiation of coagula-
ion; 2) inhibitors of the propagation of coagulation; and
) thrombin inhibitors (see the section “Direct thrombin
nhibitors”) (93).
Inhibitors of the initiation of coagulation cascade include
rugs that target tissue factor, the tissue factor-VIIa com-
lex, and active site-blocked FVIIa. A monoclonal antibody
o tissue factor demonstrated dose-related inhibition of
oagulation parameters in patients with coronary artery
isease, although unexpected mucosal bleeding occurred at
reater doses (94). A parenteral recombinant protein
rNAPc2) derived from the hematophagous hookworm
educed new thrombin generation and recurrent ischemia in
phase 2 trial of patients with NSTE-ACS managed with
ultiple antithrombotics and early catheterization (95).
lthough the addition of rNAPc2 was generally well
olerated when added to UFH or enoxaparin, some heparin
ppears necessary to avoid procedure-related thrombosis (as
as observed with fondaparinux in the OASIS 5 and 6
rials; see the section “Factor Xa inhibitors”).
Novel anticoagulants that inhibit propagation of coagu-
ation by targeting factor IXa, Xa, or their respective
ofactors (factors VIIIa, Va) are under development. As
xamples, consider the factor IXa-antidote combination
ecently described (96). These drugs are based upon aptamer
echnology, single-stranded nucleic acids that can be tai-
ored for specific targets with a high affinity. Aptamer
echnology addresses the issue of control and reversibility
hen anticoagulants are used in an acute care setting (97).
n initial study (97) with this unique approach to antico-
gulation suggest that anticoagulation (as measured by the
PTT) can be readily and predictably achieved and that the
ffects can be immediately reversed when administering an
ppropriately designed/matched antidote that also relies
pon aptamer technology. Such an approach may have value
n acute care settings where reversibility is critical, such as
uring and after cardiopulmonary bypass for coronary sur-
ery or in situations in which bleeding occurs.
onclusions
he projection that cardiovascular disease will be the
redominant cause of death for at least the next generation
98) has caught the attention of the public, media, and
olicy makers worldwide. Despite great advances in anti-
hrombotic therapies, associated high risks remain as the
esult of multifaceted interactions among patient comor-
idities, drug combinations, multifaceted dosing adjust-
ents, and the complexity of the care environment. Inndertaking efforts to develop novel antithrombotic drugs,
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Antithrombotics in ACS September 8, 2009:969–84any challenges exist (Table 3). Furthermore, the level of
vidence needed to achieve the safety and efficacy standards
equired for regulatory approval and eventual clinical accep-
ance necessitates long-term investments and takes time.
ublic and media expectations regarding the safety and
fficacy of novel therapies also add pressure on developers,
hysicians, and regulators. As novel therapies come into use,
igorous application of evidence-based medicine will be
ssential to ensure improved patient care with both current
nd novel antithrombotics.
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